
Risk-Assessment Drug Product Quality Attributes

DIA Annuai Meeting San Antonio, TX June 27, 2003

Vilayat A. Sayood , Ph.D. OGD, FDA

Drug Product Attributes Drug substance assi gned low risk status

General Principle Followed for Developing Drug Product Attributes Low Risk Low Risk Low Risk Low Medium Complexity* *DSDP characterization Mechanism of product performance Manufacturing technology



Drug Product Attributes

Dosage form Characteristics

Dosage Form Strength Physical Attributes

Drug Product Attributes

Dosage forms

IR oral solids oral solutions non sterile topical so lutions and sterile solution of simp le salts

Drug Product Attributes

Strength

IR Solids: Strength per unit NLT 1 mg or 1% w/w Oral/topical solutions drug substance concentration in drug vehicle is LT 50% and sterile solutions of simple salts drug substance concentration in drug vehicle is LT 75%

Drug Product Attributes

Physical Attributes

Are differences in physical attr ibutes of ingredients used in manufacture of drug product reported to impact pro duct performance?

Drug Product Attributes

Marketing History

Has the DP been on market for five ye ars, with two years real time stabl lity data available on a minimum of three commercial batches?

Drug Product Attributes

Release and Stabi lity Assessme nt

Release & Stability Specifications
Product Degradation Profile
Product Storage

Drug Product Attributes

Release and Stability Specification

Does the drug product specification conform to contemporary standards?

Drug Product Attributes

Product Degradation Profile

Is the drug product degradation profile predictable and are degradants controlled?

No know toxic impurities or degradants

Drug Product Attributes

Product Storage

is the drug product stored at CRT and required no special packaging?

Drug Product Attributes

Drug product to qualify as candi date for low risk assignment

Dosage form Characteristics Marketing History Release and Stability Assessment

Acknowledgement

- Drug Product Working Group
- Devinder Cill
- Ban Boring
- Liang Zhou
- Shelden Markefsky